INNMF.US Amplia Therapeutics Limited

Healthcare Biotechnology USA Stocks
0.0540 USD
Close of Nov 15, 2026
0.0500 0.2700
Market cap
USD 27.7M
P/E
-
P/B
1.02x
ROE
-19.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Mar 2026.

Is INNMF.US undervalued?

Graham number

The Graham number of Amplia Therapeutics Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Amplia Therapeutics Limited fundamental analysis

No fundamental analysis for Amplia Therapeutics Limited yet.

Amplia Therapeutics Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Amplia Therapeutics Limited

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immuno…

Full company profile